In 60 days, most in­sur­ers will be re­quired to cov­er HIV pre­ven­tion drugs and re­lat­ed ser­vices with no cost-shar­ing

The fed­er­al gov­ern­ment is­sued guid­ance Mon­day stat­ing that al­most all health in­sur­ers must cov­er HIV pre­ven­tion drugs — such as Gilead’s Tru­va­da and De­scovy — with no cost-shar­ing, as well as as­so­ci­at­ed lab test­ing and fol­low-up vis­its.

In­sur­ers were al­ready re­quired to quit charg­ing out-of-pock­et fees for the drugs, called HIV Pre­ex­po­sure Pro­phy­lax­is (PrEP), by Jan­u­ary of this year. But now in­sur­ers have 60 days to com­ply with the ad­di­tion­al re­quire­ments, in­clud­ing no-cost ser­vices like base­line and fol­low-up test­ing, as well as mon­i­tor­ing, ac­cord­ing to the guid­ance.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER